UK Budget 2026: what does it mean for early-stage biotech and life science companies?

More support for growth, but does the package fit the way biotech grows?

For an early-stage life sciences company, the most useful Budget measures are those that help fund the next experiment, recruit the next specialist or reach the next clinical milestone. On that test, this Budget offers some welcome improvements, particularly to employee share incentives and around the periphery on R&D tax administration, alongside the prospect of more investment capital. But the benefits are uneven: the largest life sciences investment announcement concerns a few well-established businesses, while the proposed Founders’ Relief is itself at foundation stage and risks overlooking companies that create substantial scientific value before generating substantial revenue.

Our overall assessment is cautiously positive on the direction of travel, but the lack of substantial immediate impact for pre-revenue companies is disappointing. This is a package with a few useful changes rather than a comprehensive answer to early-stage biotech financing. Crucially, proposed reliefs, future funding capacity and consultation commitments should not be confused with cash available to extend a company’s runway today.

SOME positives

More potential investment capital

The British Business Bank (BBB) will receive a £5 billion increase in financial capacity, including £1.4 billion for equity funds supporting high-growth businesses and £450 million for a new venture-debt product. These are cross-sector measures, but a larger domestic investment base could help specialist funds finance companies through successive development stages.

The BBB has recently demonstrated some commitment to life sciences: before the Budget, it had announced up to £135 million across two Advent Life Sciences funds, taking its committed and agreed commitments to more than £745 million across 17 life sciences funds. Those September commitments are important context, but are not new Budget money. The next question is how much of the additional capacity will reach the sector, at what stage and on what timetable.

Venture debt may broaden financing choices, but boards should not treat it as interchangeable with equity or grants. For a company whose next financing depends on a scientific or clinical milestone, repayment dates, covenants and the consequences of delay deserve at least as much attention as dilution. The venture-debt product’s detailed terms will determine its practical usefulness.

Better tools for recruiting and retaining specialists

From 6 April 2027, the Company Share Option Plan (CSOP), to be rebranded “EMI2”, is to have a £120,000 individual option limit, double the current £60,000, and a maximum tax-advantaged exercise period of 15 years rather than 10. The interaction between the CSOP and Enterprise Management Incentives (EMI) individual limits will also be removed. Subject to each scheme’s requirements, an employee could therefore hold £250,000 of EMI options alongside £120,000 of EMI2 options. These are the maximum value of the option shares tested at the date of grant of the options, not a cap on the tax-free sale proceeds.

The EMI exercise window following a disqualifying event is also to increase from 90 to 180 days from 6 April 2027. Separately, the previously announced removal of the standalone EMI grant notification will apply to options granted on or after that date, with grants instead reported through the annual return.

The detailed rules will need to confirm whether, and on what terms, the changes will benefit options already granted, including whether existing exercise periods can be extended. It is hoped that this will be the case given the treatment of other EMI changes over the past few years.

Longer exercise periods and greater flexibility are a good fit for businesses with lengthy development cycles. But better option rules do not automatically mean a better exit-tax outcome for every employee: the reduction in Business Asset Disposal Relief discussed below needs to be considered alongside the incentive improvements.

Less process around R&D tax relief

The short-lived and needlessly bureaucractic requirement to submit an R&D Claim Notification Form is to be removed for claims made on or after 1 April 2027. The Additional Information Form is to be simplified and rationalised from autumn 2027. These changes should reduce administrative friction, particularly for smaller companies, but there is no increase to R&D credits themselves nor any relaxation of the onerous requirements to substantiate eligible activity and costs as BioUK has been arguing would be welcome for investment in the sector.

The wider simplification programme will also be relevant. It will examine the Enhanced R&D Intensive Support (ERIS) expenditure ratio, connected-company rules, the PAYE/NIC cap and going-concern requirements. These are issues BioUK will be engaging on.

A practical VAT improvement for clinical-stage businesses

An announcement deserving more attention is the proposed VAT zero rate for medicines supplied free of charge for qualifying purposes, with effect from 23 June 2026. The announced scope includes NHS treatment, the Early Access to Medicines Scheme and other early-access arrangements, clinical trials and continued treatment after a trial. This is a useful removal of a tax barrier for such programmes.

Investment schemes and regulatory reform

The Budget also proposes technical fixes to SEIS, EIS and VCT rules, mostly from 6 April 2027, together with work on Advance Assurance and fee transparency. These are useful improvements to the operation of key fundraising reliefs, though a broader increase in investment limits would have been welcomed considering broader inflationary pressures continuing to hit the sector. One very welcome change to the rules is to permit SEIS and EIS investments to complete on the same day, which has been a long-standing complication and trip-hazard to the venture capital relief schemes, often overlooked by companies.

SOME concerns

The £1 billion life sciences announcement is not a new SME grant pot

The headline grabbed refers to investments by Convatec, Vertex Pharmaceuticals and Kindeva, backed by almost £70 million of government grants. Convatec plans over £500 million over the next decade for a global R&D hub in Manchester; Vertex over £300 million for a new Oxford facility; and Kindeva £200 million in Loughborough to strengthen respiratory-medicines manufacturing.

These investments may strengthen research clusters, partnerships and supply chains. However, they do not represent a meaningful amount of government funding made available for early-stage companies, nor a new fund to bridge the gap between discovery and commercial development. For a seed-stage biotech, the potential benefit is predominantly indirect.

Founders’ Relief: an attractive rate, but a difficult fit for pre-revenue biotech?

A new proposed relief would apply a 10% CGT rate to up to £10 million of lifetime qualifying gains for disposals from 6 April 2027. However, the devil will be in the detail, and the relief is still subject to technical consultation and subsequent legislation. Under the proposed design, the limit would be reduced by amounts claimed under BADR and Investors’ Relief from that date. BioUK intends to respond to the technical consultation to ensure the potential benefits can support the sector.

The main proposed conditions include:

An initial holding of at least 25% of ordinary share capital with corresponding voting and economic rights; a five-year holding period; and at least five continuous tax years of UK residence before disposal.

Company-level conditions including a substantial UK presence for the preceding five accounting periods, at least £10 million turnover and at least 15 qualifying full-time employees in the accounting period before disposal. Directors, contractors and agency workers would not count towards that employee test.

At least two of three additional tests: 25% annual average compound turnover growth over three consecutive accounting periods within the previous ten years, from a £10 million turnover base; corresponding headcount growth from a base of at least 15 employees; or at least £1.5 million of qualifying R&D expenditure for which relief has been claimed in periods ending within the preceding three years.

One key point is that R&D expenditure alone is not an alternative route around the minimum turnover and employee conditions. A pre-revenue company would fail the proposed £10 million turnover threshold even if it passed the innovation test. And a company relying on that innovation test would still need one of the two growth tests.

That creates a potential mismatch for a sector in which value may be realised through licensing or acquisition before substantial product sales – indeed, for many companies, the only way for progressing through clinical trials is to be acquired by a larger entity and this may be prior to any sales at all. A multi-founder university spin-out may also struggle with the initial 25% ownership test, while an outsourced development model may be poorly served by a test excluding contractors. These are reasons to seek better-targeted criteria, not to dismiss the principle of rewarding successful founders. Clinical progress, validated IP and follow-on investment deserve consideration as possible evidence of value creation.

The consultation closes soon – on 30 November 2026. Whilst it is positive that the relief is intended to come in for disposals from 6 April 2026, this does not allow much room to influence the relief, let alone restructure existing operations with a view to adherence to the relief.

BADR is being reduced, once again

The proposed Founders’ Relief sits alongside a further reduction in the BADR lifetime limit from £1 million to £500,000 for qualifying disposals on or after 6 April 2027.

What should early-stage companies do now?

• Policy: submit practical examples to the Founders’ Relief consultation by 30 November, particularly where scientific progress and company value precede turnover.
• Finance: track BBB-backed specialist funds and the venture-debt product, but keep financing plans grounded in confirmed eligibility, terms and deployment dates.
• People: review EMI and prospective EMI2 arrangements, leaver provisions and employee communications ahead of April 2027.
• R&D: maintain current compliance and strong technical records; identify specific ERIS and claims-process problems to feed into simplification work.
• Pre-exits: model the proposed Founders’ Relief and reduced BADR limit

The longer-term outlook

• There is some scope for a positive reading of this Budget and we welcome the combination of founder incentives, employee share schemes and investment capacity. Those benefits should not be lost in a discussion dominated by what the Budget did not deliver.
• That said, the test for early-stage life sciences is more demanding than the announcement of large investment totals. There still needs to be faster deployment of innovation funding, more sector-targeted BBB support, and stronger R&D relief. The package makes some progress on elements of that agenda, but minor administrative simplification is not an increase in the R&D credit, and backing established-company investment is not the same as financing the next generation.
• Better incentive tools, simpler claims and a deeper funding base are worth having. The priority now is delivery, and a Founders’ Relief design that recognises the way research-led businesses actually build value. For early-stage biotech, success should be measured not only by the size of the eventual exit, but by whether promising science can secure the people and capital needed to get there.

Authors: Graham Samuel-Gibbon (Winston Taylor) and Kathy Potter (Penningtons Manches Cooper) – members of BioUK’s Investment & Tax Advisory Group (ITAG)